NCT03986801 (PASS-MULTI) is a NA clinical trial of pharmaceutical interview in Vulnerable Patients, sponsored by Assistance Publique Hopitaux De Marseille.

Who is sponsoring NCT03986801?

NCT03986801 is sponsored by Assistance Publique Hopitaux De Marseille.

What drugs are being tested in NCT03986801?

Interventions in NCT03986801: pharmaceutical interview.

What condition does NCT03986801 study?

NCT03986801 studies Vulnerable Patients.

Is NCT03986801 still recruiting?

NCT03986801 is currently status unknown. Last updated 14 June 2019.

Last reviewed 2019-06-14 · How we verify

NCT03986801: PASS-MULTI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Impact of a Permanently Maintained Healthcare Multidisciplinary Facility (PASS-MULTI) on Unscheduled Readmissions at 12 Months for Persons in Precarious Situations.

Status unknown NA Last updated 14 June 2019

What this trial tests

NA trial testing pharmaceutical interview in Vulnerable Patients in 1,858 participants. Status unknown.

Timeline

2 September 2019

Primary endpoint
2 September 2020

2 September 2021

Quick facts

Lead sponsor	Assistance Publique Hopitaux De Marseille
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	1,858
Start date	2 September 2019
Primary completion	2 September 2020
Estimated completion	2 September 2021
Sites	1 location across France

Drugs / interventions tested

pharmaceutical interview

Conditions studied

Vulnerable Patients — all drugs for Vulnerable Patients →

Sponsor

Assistance Publique Hopitaux De Marseille — full company profile →

Who can join

18 and older, any sex, with Vulnerable Patients. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Created in 1998, PASS departments are mostly intrahospital structures providing primary care to vulnerable patients. The main objective of the project will be to measure the impact of a multidisciplinary PASS benefiting from outpatient pharmaceutical interviews on the rate of unplanned rehospitalization of patients in precarious situations. The impact of the implementation of such a device will also be measured on other indicators of major interest in the course of care of the precarious patient: average lengths of stay, emergency room, improved continuity of treatment, quality of life of the patient related to his health, medication compliance, effective accessibility to social rights, qualitative improvement in the use of care, medico-economic efficiency of the intervention compared to existing practice. The study will be multicenter: 6 centers spread throughout France (Marseille, Paris, Nice, Toulouse, Poitiers and Bayonne).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of pharmaceutical interview

Trials testing the same drug.

NCT05248490 — Impact of Pharmaceutical Interviews Regarding the Management of Adverse Effects Related to the Antibiotic Therapy Used t · NA · completed

Other Assistance Publique Hopitaux De Marseille trials

Trials by the same sponsor.

NCT07521644 — Dysbiosis of Methanogenic Archaea and Nanoarchaea in the Oral Microbiome · NA · not yet recruiting
NCT07357025 — Resting-State fMRI Study of Functional Connectivity After Gamma Knife Radiosurgery in Trigeminal Neuralgia · NA · not yet recruiting
NCT07356661 — Evaluation of the Efficacy of Neurofeedback Technique Based on EEG Desynchronization in Epileptic Patients · NA · not yet recruiting
NCT07399327 — Biomarkers of Response to SEEG Thermocoagulation · NA · not yet recruiting
NCT06999499 — Development of an Aid to Melanoma Detection Using Artificial Intelligence Algorithms Based on Images From the VECTRA 3D · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03986801 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assistance Publique Hopitaux De Marseille
Last refreshed: 14 June 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03986801.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing